Levothyroxine Sodium Tablets Recalled for Out-of-Specification Potency
Mylan Institutional is recalling Levothyroxine Sodium Tablets 150 mcg due to out-of-specification potency. The medication tested higher than specified, affecting 347 cartons distributed nationwide (Lot 3116074, expires 09/30/2025).
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II drug recall with out-of-specification potency identified. No reported illnesses or hospitalizations. Qualifies as a risk-of-harm product where injury has not yet been reported, per rubric Score 3 criteria.
Plain-English summary
Mylan Institutional, Inc. is recalling Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), in 100 Unit Dose Blister Cards format. The recall affects 347 cartons distributed nationwide.
The recall was initiated due to out-of-specification potency results. Testing showed the tablets contained higher potency than specified. The affected lot is 3116074, with an expiration date of September 30, 2025. The product was manufactured in India.
Patients taking this medication should contact their pharmacy or healthcare provider regarding this recall. Patients should not discontinue levothyroxine, a critical thyroid hormone, without guidance from their healthcare provider.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Mylan Institutional, Inc.
- Category
- Drug
- Hazard
- out-of-specification
- super-potency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot 3116074
- Exp. 09/30/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEVOTHYROXINE SODIUM
- ModerateLevothyroxine Sodium 300 mcg Tablets Recalled for Subpotency
FDA (Drugs) · 2026-07-08
- LowLevothyroxine Sodium tablets recalled for foreign substance contamination
FDA (Drugs) · 2025-06-18
- ModerateLevothyroxine Sodium Tablets Nationwide Recall Due to Subpotency
FDA (Drugs) · 2025-05-07
- ModerateLevothyroxine Sodium Tablets Recalled for Subpotency by Accord Healthcare
FDA (Drugs) · 2025-05-07
- HighLevothyroxine Sodium Tablets 88 mcg Recall for Subpotency
FDA (Drugs) · 2025-05-07
Same category
- ModerateQuality Choice Earwax Removal Kit Carbamide Peroxide Subpotent Drug Recall
FDA (Drugs) · 2026-07-22
- ModerateFamily Wellness Carbamide Peroxide Earwax Removal Kit Subpotent Drug
FDA (Drugs) · 2026-07-22
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- ModerateLeader Carbamide Peroxide Earwax Removal Kit Recalled for Subpotency
FDA (Drugs) · 2026-07-22
- ModerateNystatin Cream Recall Due to Low Potency Test Results
FDA (Drugs) · 2026-07-22